Sunday, July 21, 2024
HomeCOVID-19Ivermectin can cut Covid mortality by 92 per cent, says major study

Ivermectin can cut Covid mortality by 92 per cent, says major study


REGULAR use of ivermectin led to a 100 per cent reduction in hospitalisation rate, a 92 per cent reduction in mortality rate and an 86 per cent reduction in the risk of dying from a Covid-19 infection when compared with non-users, a major study has found.

The study, published in the medical journal Cureus, analysed data from 223,128 people from the city of Itajaí in Brazil, making it the largest study of its kind and giving its findings a high degree of certainty. Senior author Dr Flavio A Cadegiani wrote on Twitter: ‘An observational study with the size and level of analysis as ours is hardly achieved and infeasible to be conducted as a randomised clinical trial. Conclusions are hard to be refuted. Data is data, regardless of your beliefs.’

The study compared those who took ivermectin regularly, irregularly and not at all prior to being infected with Covid-19 (i.e. as prophylaxis), and found a dose-dependent relationship, confirming that the difference in outcomes is very likely to be due to the drug and not other factors, such as differences between the groups.

The programme used ivermectin at a dose of 0.2 mg/kg/day for two consecutive days, every 15 days, for 150 days. ‘Regular’ users had 180 mg or more of ivermectin in total and ‘irregular’ users had up to 60 mg.

The authors used a technique called ‘propensity score matching’ to control for confounding factors that may otherwise have biased the study in one direction or another. For example, those taking ivermectin tended to be older than those not taking it (average age 47 years vs 40 years), but by matching people of similar age in each group and comparing outcomes this confounding factor was controlled for.

The authors draw particular attention to the dose-dependent relationship as confirming the efficacy of the treatment: ‘The response pattern of ivermectin use and level of protection from Covid-19-related outcomes was identified and consistent across dose-related levels. The reduction in Covid-19 infection rate occurred in a consistent and significant dose-dependent manner, with reductions of 49 per cent and 32 per cent in regular and irregular users, when compared to non-users. The most striking evidence of ivermectin’s effectiveness was the 100 per cent reduction in mortality for female regular users.’

The data in the study come from official government databases and, according to the authors, ‘conclusively show that the risk of dying from Covid-19 was lower for all regular and irregular users of ivermectin, compared to non-users, considering the whole population’.

The study, while not a randomised controlled trial (RCT), used a ‘strictly controlled population with a great level of control for confounding factors’ and was larger than would be feasible in an RCT.

The authors highlight a ‘notable reduction in risk of death in the over 50-year-old population and those with comorbidities’.

They conclude that the evidence provided by the study is ‘among the strongest and most conclusive data regarding ivermectin efficacy’.

Many governments have suppressed the use of ivermectin to treat COVID-19, claiming there is a lack of evidence of efficacy. However, this purported lack of evidence often relies on poorly designed trials and biased conclusions.

One of the new study’s authors and a seasoned proponent of repurposed treatments like ivermectin, Dr Pierre Kory, made clear his thoughts on Twitter in April as he responded to an FDA tweet reminding the public that ivermectin is not approved: ‘Messaging BS with one corrupt study while ignoring 82 trials (33 RCTs) from 27 countries, 129K patients – sum showing massive benefits. Stop lying man, people are dying. #earlytreatmentworks.’

Social media companies have censored information about ivermectin, often considering any suggestion that it is an effective treatment for COVID-19 to be misinformation. Yet ivermectin is a cheap, safe drug that many studies have shown brings considerable benefit in treating and preventing Covid-19. The latest study impressively confirms its efficacy as a prophylactic.

Shockingly, most governments still do not have a protocol for early treatment or prevention of Covid-19. The NHS says treatment is available only for those at high risk of serious disease who have a positive test and symptoms that are not getting better. Its guidance on self-care for people ill at home recommends paracetamol and ibuprofen. Yet here is a highly controlled study of over 200,000 people that shows huge benefit – 92 per cent reduction in mortality, 100 per cent reduction in hospitalisation – for the prophylactic use of a cheap, widely available drug, and which confirms the results of multiple earlier studies. What are our governments waiting for? What more do they need to approve drugs that have been shown to save lives?

This appeared in the Daily Sceptic on September 3, 2022, and is republished by kind permission.

If you appreciated this article, perhaps you might consider making a donation to The Conservative Woman. Unlike most other websites, we receive no independent funding. Our editors are unpaid and work entirely voluntarily as do the majority of our contributors but there are inevitable costs associated with running a website. We depend on our readers to help us, either with regular or one-off payments. You can donate here. Thank you.
If you have not already signed up to a daily email alert of new articles please do so. It is here and free! Thank you.

Will Jones
Will Jones
Will Jones is editor of the Daily Sceptic.

Sign up for TCW Daily

Each morning we send The ConWom Daily with links to our latest news. This is a free service and we will never share your details.